These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37844857)

  • 1. Should we use nintedanib as early therapy in patients with SSc-ILD?
    Zanatta E; Moccaldi B; Szucs G; Spagnolo P
    Autoimmun Rev; 2024 Jan; 23(1):103463. PubMed ID: 37844857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
    Yamasaki Y; Kuwana M
    Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
    Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
    Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease.
    Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M
    Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab plus Nintedanib for progressive interstitial lung disease in systemic sclerosis: a one-year observational study.
    Panopoulos S; Tzilas V; Bournia VK; Tektonidou MG; Sfikakis PP
    Rheumatol Int; 2024 Oct; 44(10):1959-1966. PubMed ID: 39180531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
    Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
    Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial Lung Disease: How Should Therapeutics Be Implemented?
    Bruni C; Campochiaro C; de Vries-Bouwstra JK
    Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care.
    Mendoza FA; Allawh T; Jimenez SA
    Clin Exp Rheumatol; 2023 Aug; 41(8):1704-1712. PubMed ID: 37382458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifibrotics in systemic sclerosis.
    Martin-Lopez M; Carreira PE
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101671. PubMed ID: 33839046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
    Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
    Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nintedanib Therapy Alone and Combined with Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: Systematic Reviews and Meta-analysis.
    Herman D; Ghazipura M; Barnes H; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Mar; 21(3):474-485. PubMed ID: 37773000
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
    Raghu G; Montesi SB; Silver RM; Hossain T; Macrea M; Herman D; Barnes H; Adegunsoye A; Azuma A; Chung L; Gardner GC; Highland KB; Hudson M; Kaner RJ; Kolb M; Scholand MB; Steen V; Thomson CC; Volkmann ER; Wigley FM; Burlile D; Kemper KA; Knight SL; Ghazipura M
    Am J Respir Crit Care Med; 2024 Jan; 209(2):137-152. PubMed ID: 37772985
    [No Abstract]   [Full Text] [Related]  

  • 14. [Modern drug therapy for systemic sclerosis associated interstitial lung disease].
    Aringer M; Koschel D; Krause A; Schneider U; Gläser S
    Dtsch Med Wochenschr; 2022 Feb; 147(4):179-186. PubMed ID: 34861699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [How do I treat interstitial lung disease in systemic sclerosis?].
    Riemekasten G
    Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease.
    Wollin L; Trinh-Minh T; Zhang Y; Distler JHW
    Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interstitial Lung Disease Associated with Systemic Sclerosis.
    Mismetti V; Si-Mohamed S; Cottin V
    Semin Respir Crit Care Med; 2024 Jun; 45(3):342-364. PubMed ID: 38714203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
    Allanore Y; Khanna D; Smith V; Aringer M; Hoffmann-Vold AM; Kuwana M; Merkel PA; Stock C; Sambevski S; Denton CP;
    Rheumatology (Oxford); 2024 Mar; 63(3):639-647. PubMed ID: 37294870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of nintedanib-induced gastrointestinal adverse events between patients with systemic sclerosis-associated interstitial lung disease and idiopathic interstitial pneumonias.
    Imai M; Okabayashi H; Akaike K; Hamada S; Masunaga A; Ichiyasu H; Sakagami T
    Respir Investig; 2024 May; 62(3):317-321. PubMed ID: 38395006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
    Kuwana M; Azuma A
    Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.